JLPC(SH:600513)2025-04-29 12:08Financial Performance - The company's operating revenue for Q1 2025 was CNY 627,705,511.57, representing an increase of 18.78% compared to CNY 528,459,397.27 in the same period last year[3]. - The net profit attributable to shareholders decreased by 29.15% to CNY 23,059,579.59 from CNY 32,545,358.40 year-on-year[3]. - The diluted earnings per share decreased by 27.27% to CNY 0.08 from CNY 0.11 in the same period last year[3]. - The total comprehensive income for Q1 2025 was CNY 27,299,960.86, compared to CNY 36,917,239.32 in Q1 2024, reflecting a decline of approximately 26%[17]. - The company's total profit before tax was CNY 41,458,668.98, down from CNY 46,578,061.07 in the same quarter last year[17]. Cash Flow and Assets - The net cash flow from operating activities was negative at CNY -53,095,863.93, a significant decline from CNY -17,883,555.80 in the previous year[3]. - The company's cash and cash equivalents increased to RMB 267,965,447.30 as of March 31, 2025, compared to RMB 227,719,824.05 at the end of 2024, representing a growth of 17.6%[12]. - The cash and cash equivalents at the end of Q1 2025 were CNY 242,132,899.33, an increase from CNY 198,636,200.73 at the end of Q1 2024[21]. - The company's total assets increased by 20.01% to CNY 3,623,581,957.21 from CNY 3,019,472,551.13 at the end of the previous year[3]. - The company's total liabilities increased to RMB 1,837,697,492.41 as of March 31, 2025, compared to RMB 1,442,257,062.11 at the end of 2024, reflecting a rise of 27.5%[14]. Operating Costs and Expenses - Total operating costs for Q1 2025 were RMB 587,869,188.52, up from RMB 481,823,038.52 in Q1 2024, reflecting a year-over-year increase of 22.0%[16]. - The company incurred a total operating expense of CNY 709,968,744.24, which increased from CNY 622,108,376.05 in the previous year[20]. - The company's net profit for Q1 2025 was impacted by an increase in R&D expenses, which rose to RMB 22,273,387.47 from RMB 17,743,834.23 in Q1 2024, an increase of 25.5%[16]. Investments and Mergers - The company’s long-term investments decreased to RMB 1,393,424.93 as of March 31, 2025, down from RMB 2,590,232.10 at the end of 2024, a decline of 46.1%[13]. - The company’s subsidiary Nanjing Lianzhihua has completed the absorption merger with Nanjing Diyihua, streamlining operations and improving capital efficiency[10]. Product Development and Approvals - The company completed the enrollment of participants in the Phase III clinical trial for the new drug LH-1801, aimed at evaluating its efficacy and safety in a broader patient population[9]. - The company received a drug registration certificate for Amlodipine Besylate and Olmesartan Medoxomil Tablets, enhancing its product line and market competitiveness[9]. - The company obtained a supplementary approval notice for Methanesulfonic Acid Phenol Injection, which passed the consistency evaluation for generic drug quality and efficacy[9]. - The company has received drug registration certificates for new products, enhancing its product line and market competitiveness[10]. Other Financial Metrics - The weighted average return on net assets decreased by 0.73 percentage points to 1.64% from 2.37% year-on-year[3]. - The company reported non-recurring gains and losses totaling CNY 909,108.80 for the period[7]. - The total revenue from operating activities was CNY 656,872,880.31, up from CNY 604,224,820.25 in the same period last year, representing an increase of approximately 8.7%[20]. - The company reported a significant increase in cash inflow from financing activities, totaling CNY 534,387,620.14, compared to CNY 159,700,000.00 in Q1 2024[21]. - The company reported an increase in investment activities cash outflow to CNY 194,255,050.09, compared to CNY 34,576,429.51 in Q1 2024[21].